Your browser doesn't support javascript.
loading
Splenic red pulp macrophages provide a niche for CML stem cells and induce therapy resistance.
Bührer, Elias D; Amrein, Michael A; Forster, Stefan; Isringhausen, Stephan; Schürch, Christian M; Bhate, Salil S; Brodie, Tess; Zindel, Joel; Stroka, Deborah; Sayed, Mohamad Al; Nombela-Arrieta, César; Radpour, Ramin; Riether, Carsten; Ochsenbein, Adrian F.
Afiliación
  • Bührer ED; Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Amrein MA; Tumor Immunology, Department for BioMedical Research, University of Bern, Bern, Switzerland.
  • Forster S; Graduate School of Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
  • Isringhausen S; Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Schürch CM; Tumor Immunology, Department for BioMedical Research, University of Bern, Bern, Switzerland.
  • Bhate SS; Graduate School of Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
  • Brodie T; Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Zindel J; Tumor Immunology, Department for BioMedical Research, University of Bern, Bern, Switzerland.
  • Stroka D; Graduate School of Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
  • Sayed MA; Department of Medical Oncology and Hematology, University Hospital and University of Zürich, Zürich, Switzerland.
  • Nombela-Arrieta C; Institute of Pathology, University of Bern, Bern, Switzerland.
  • Radpour R; Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.
  • Riether C; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
  • Ochsenbein AF; Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany.
Leukemia ; 36(11): 2634-2646, 2022 11.
Article en En | MEDLINE | ID: mdl-36163264
ABSTRACT
Disease progression and relapse of chronic myeloid leukemia (CML) are caused by therapy resistant leukemia stem cells (LSCs), and cure relies on their eradication. The microenvironment in the bone marrow (BM) is known to contribute to LSC maintenance and resistance. Although leukemic infiltration of the spleen is a hallmark of CML, it is unknown whether spleen cells form a niche that maintains LSCs. Here, we demonstrate that LSCs preferentially accumulate in the spleen and contribute to disease progression. Spleen LSCs were located in the red pulp close to red pulp macrophages (RPM) in CML patients and in a murine CML model. Pharmacologic and genetic depletion of RPM reduced LSCs and decreased their cell cycling activity in the spleen. Gene expression analysis revealed enriched stemness and decreased myeloid lineage differentiation in spleen leukemic stem and progenitor cells (LSPCs). These results demonstrate that splenic RPM form a niche that maintains CML LSCs in a quiescent state, resulting in disease progression and resistance to therapy.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Leucemia Mieloide Límite: Animals / Humans Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Suiza

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Leucemia Mieloide Límite: Animals / Humans Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Suiza